Back

HanAll Biopharma halts CLE trials after China rights setback

Verifying
  • HanAll Biopharma halted clinical trials for its cutaneous lupus erythematosus treatment candidate.
  • HanAll Biopharma failed to reclaim its China business rights.
  • Daewoong Pharmaceutical owns HanAll Biopharma as a subsidiary.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.